Argininosuccinate synthase (AS) catalyzes the ratelimiting step in the recycling of citrulline to arginine, which in endothelial cells, is tightly coupled to the production of nitric oxide (NO). In previous work, we established that endothelial AS mRNA can be initiated from multiple start sites, generating co-expressed mRNA variants with different 5-untranslated regions (5-UTRs). One of the 5-UTRs, the shortest form, represents greater than 90% of the total AS mRNA. Two other extended 5-UTR forms of AS mRNA, resulting from upstream initiations, contain an out-of-frame, upstream open reading frame (uORF). In this study, the function of the extended 5-UTRs of AS mRNA was investigated. Single base insertions to place the uORF in-frame, and mutations to extend the uORF, demonstrated functionality, both in vitro with AS constructs and in vivo with luciferase constructs. Overexpression of the uORF suppressed endothelial AS protein expression, whereas specific silencing of the uORF AS mRNAs resulted in the coordinate up-regulation of AS protein and NO production. Expression of the full-length of the uORF was necessary to mediate a trans-suppressive effect on endothelial AS expression, demonstrating that the translation product itself affects regulation. In conclusion, the uORF found in the extended, overlapping 5-UTR AS mRNA species suppresses endothelial AS expression, providing a novel mechanism for regulating endothelial NO production by limiting the availability of arginine.
Nitric oxide (NO)1 synthesized from arginine by endothelial nitric-oxide synthase is a potent vasodilator and a critical modulator of blood flow and blood pressure. In addition, it mediates vasoprotective actions through inhibiting smooth muscle proliferation, platelet aggregation, and leukocyte adhesion (1-3). Under pathophysiological conditions associated with endothelial dysfunction, such as heart failure (4), hypertension, hypercholesterolemia, atherosclerosis (5), and diabetes (6), the ability to produce NO seems to be impaired. Paradoxically, NO production can be impaired by limited availability of the substrate arginine, despite apparently saturating levels of intracellular and extracellular arginine (7-10). We have previously shown that under normal conditions, the essential arginine available for NO production is derived from the recycling of citrulline to arginine, catalyzed by two enzymes, argininosuccinate synthase (AS) and argininosuccinate lyase (AL) (11,12). Although these two enzymes have been studied extensively in liver, where they participate in the urea cycle (13), it was not until the discovery of NO that their function in non-hepatic tissues was clarified. In endothelial cells, AS and AL play a critical role in the operation of a citrulline-NO cycle, which supports endothelial NO production (14 -17).Because AS catalyzes the rate-limiting step in the citrulline-NO cycle (15), our initial studies have focused on the molecular basis for the functional role of endothelial AS. Endothelial and hepatic AS appear to have the same ...